Trends in utilization of hypofractionated whole breast irradiation (HF-WBI) in triple negative breast cancer (TNBC): a national cancer database (NCDB) analysis

Breast Cancer Research and Treatment
Stephanie R RiceElizabeth M Nichols

Abstract

We sought to identify trends over time with respect to the use of hypofractionated whole breast irradiation (HF-WBI) in women with triple negative breast cancer (TNBC) in the national cancer database (NCDB). Trends in utilization of HF-WBI in women diagnosed with T1-2N0 TNBC in the NCDB between 2008 and 2013 were analyzed. Case-matched luminal A women were used for comparison. Variables included age, race, year of diagnosis, insurance status, income quartile, receipt of neoadjuvant chemotherapy, and institution (academic vs. community). Chi square, logistic regression, and multivariate analysis was performed. Utilization of HF-WBI among the 53,269 TNBC women identified steadily increased from 4.7% in 2008 to 14.0% in 2013 for women with TNBC compared to luminal A cancer whose utilization increased from 7.3 to 23.3% over the same time frame (p < 0.001). On univariate analysis, HF-WBI was associated with increasing age (p < 0.001), Medicare insurance (p < 0.001), race (p = 0.041), diagnosis after 2011 (p < 0.001), higher income quartile (p < 0.001), and treatment at academic institutions (p < 0.001). On multivariate analysis, age (p < 0.001, OR 1.038 per year), income quartile (p = 0.002, OR 1.061 per increase in quartile), treat...Continue Reading

References

May 10, 2005·Radiotherapy and Oncology : Journal of the European Society for Therapeutic Radiology and Oncology·John YarnoldRoger Owen
Aug 3, 2007·Clinical Cancer Research : an Official Journal of the American Association for Cancer Research·Rebecca DentSteven A Narod
Jan 4, 2008·Histopathology·J S Reis-Filho, A N J Tutt
Jan 10, 2008·Annals of Surgical Oncology·Karl Y BilimoriaClifford Y Ko
May 20, 2008·Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology·Emad A RakhaIan O Ellis
Apr 4, 2009·Cancer Causes & Control : CCC·Katrina F TriversJ William Eley
Jan 27, 2010·Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology·Daniel P SilverJudy E Garber
Feb 12, 2010·The New England Journal of Medicine·Timothy J WhelanCarolyn Freeman
Jul 20, 2010·International Journal of Radiation Oncology, Biology, Physics·Benjamin D SmithBruce G Haffty
Nov 12, 2010·The New England Journal of Medicine·William D FoulkesJorge S Reis-Filho
Jan 15, 2011·Clinical Cancer Research : an Official Journal of the American Association for Cancer Research·Ana M Gonzalez-AnguloFunda Meric-Bernstam
Feb 25, 2014·Annals of Oncology : Official Journal of the European Society for Medical Oncology·A L BaneM N Levine
Dec 11, 2014·JAMA : the Journal of the American Medical Association·Justin E BekelmanEzekiel J Emanuel
Dec 30, 2014·International Journal of Radiation Oncology, Biology, Physics·Reshma JagsiRonald C Chen
Dec 30, 2014·International Journal of Radiation Oncology, Biology, Physics·Reshma JagsiUNKNOWN Michigan Radiation Oncology Quality Consortium
Apr 8, 2015·Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology·Steven J IsakoffLeif W Ellisen
Jan 10, 2018·CA: a Cancer Journal for Clinicians·Rebecca L SiegelAhmedin Jemal
Sep 12, 2018·Advances in Radiation Oncology·Philip GilboLucille Lee

❮ Previous
Next ❯

Citations

Jan 17, 2020·The Breast Journal·Meena S Moran, Pauline T Truong

❮ Previous
Next ❯

Related Concepts

Related Feeds

Breast Cancer Triple-N

Breast cancer cells have receptors for estrogen, progesterone, HER2 receptors (also called ERBB2). Triple-negative breast cancers do not have any of these receptors. Here are the latest discoveries pertaining to triple-negative breast cancers.

Cancer Disparities

Cancer disparities refers to differences in cancer outcomes (e.g., number of cancer cases, related health complications) across population groups.

Breast Cancer: Chemo-Resistance

Some cancers are difficult to treat and aggressive including the "triple-negative" breast cancer. This type of cancer is chemoresistant even before chemotherapy begins. Here are the latest discoveries chemo-resistance in breast cancer.